NeurologyLive Friday 5 — September 10, 2021

Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Roundtable Discussion: Transforming the Future of TSC Care, Research

To spread the word about the several ongoing campaigns and advancements within the field, NeurologyLive partnered with the TSC Alliance for a roundtable discussion that featured experts Peter Crino, MD, and Steven Roberds, PhD. Crino, chairman of the Department of Neurology at the University of Maryland, and Roberds, chief executive officer of the TSC Alliance, have both been a part of the field for at least 2 decades.

2: Mind Moments Ep. 46: Tackling Barriers to Migraine Care

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Deena Kuruvilla, MD, about the issues that migraine specialists need to overcome—such as access to therapy—the real-world use of novel treatments for headache disorders, and the advances that are currently in the research and development stage.

3: NeuroVoices: Paul G. Mathew, MD, on Educating Clinical Community on Nerve Block Surgery Benefits

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed unmet needs of care for patients with neuromyelitis optica spectrum disorder, providing context on the recent advances within the field, areas that still need to be addressed, and mechanisms that have high potential to target.

4: FDA Action Update, August 2021: Approvals, Submissions, and Designations

The FDA was busy in the month of August, granting a number of different approvals and designations to new therapies for neurologic disease. Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive team.

5: No Significant Increase in Recurrent ICH When Restarting Antiplatelet Therapy

Investigators extended the follow-up period of the Restart of Stop Antithrombotics Randomized Trial (RESTART; ISRCTN71907627), which concluded that antiplatelet therapy was safe for up to 5 years following intracerebral hemorrhage, offering some solace to physicians about the use of antiplatelet therapy in this patient population.

The 3rd Annual International Congress on the Future of Neurology® is next week! The virtual meeting, which will showcase the most recent advancements in neurologic disorders, is being held September 17-18, 2021. The target audience for this activity is physicians who treat patients with neurologic disorders. Fellows, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the management of patients with neurologic disorders are also invited to participate.

The learning objectives of the program are:

• Outline current and emerging diagnostic concepts for neurologic disorders
• Explain clinical evidence for the management of neurologic disorders across multiple lines of care
• Summarize the mechanism of action of therapeutic agents used to manage neurologic disorders
• Prepare strategies for early recognition and management of treatment-related toxicities associated with neurologic therapies
• Apply multidisciplinary care strategies for optimizing patient outcomes in the setting of neurologic disorders
• Assess recent landmark data from clinical trials in the context of evolving treatment paradigms in neurology